10:45 AM EDT, 04/23/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target by $2 to $16, valuing IVZ shares at 8.6x our 2025 adjusted EPS estimate of $1.85 (cut today by $0.05) and at 10x our 2024...

11:45 AM EDT, 04/23/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target of $6.50, down $0.50, reflects a 3.4x multiple of EV to projected '25 EBITDA, a discount to JBLU's historical average. We think a discount is merited due...

12:45 PM EDT, 04/23/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $3 to $108, implying a 2024 P/E of 15.4x, largely in line with the peer average. Novartis ( NVS ) raised its full-year 2024...

11:40 AM EDT, 04/23/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We decrease our target price by $165 to $465, 27.4x our 2025 EPS estimate, a discount to MSCI's ( MSCI ) 10-year forward P/E average of 36.4x given reduced growth...